Printer Friendly

ELAN ADDS $200 MILLION OF NICOTINE PATCH PRODUCTION CAPACITY WITH SECOND UNIT; U.S. MARKET SHARE NOW AT 30 PERCENT

ELAN ADDS $200 MILLION OF NICOTINE PATCH PRODUCTION CAPACITY WITH SECOND
 UNIT; U.S. MARKET SHARE NOW AT 30 PERCENT
 ATHLONE, Ireland, June 15 /PRNewswire/ -- Elan Corporation, plc (AMEX: ELN), said it has increased its annual production capacity for nicotine patches by $200 million with installation of a second unit at its main manufacturing facility in Athlone.
 The new unit, which increases capacity up to $400 million yearly, was installed in response to high U.S. demand for Elan's ProStep(TM) patch, marketed by American Cyanamid's Lederle Laboratories division, and continuing sales in several non-U.S. markets, including South Korea, Italy and Southeast Asia. Approvals are in hand from three other countries, Germany, Denmark and Greece, with others expected shortly.
 According to the most recent IMS data, Elan's patch has gained a 16 percent total market share and a 30 percent share of the 21-22 mg dose segment of the U.S. nicotine patch market in less than six months. Elan said a new low dose strength will be available shortly.
 In early March, just weeks after ProStep's approval by the U.S. Food and Drug Administration, Elan stepped up production in response to ProStep's rapid market share gains and to also help alleviate general nicotine patch shortages in certain markets such as Boston and parts of New Jersey.
 The capacity expansion at Elan is believed to be first among the three current patch producers (Elan, Alza, Ciba-Geigy) since U.S. marketing began in December 1991 and Elan officials said it will enable Lederle to exploit any further supply shortages of competing patches. At the present time, Lederle orders are backlogged by about $20 million and the new capacity will help reduce this situation.
 "Lederle has done a tremendously successful job in differentiating and positioning ProStep in a very competitive market, especially considering it was the third patch approved," said Donald E. Panoz, Elan's chairman and CEO. "In simple terms, they are outflanking the others with smarter detailing and distribution, and a much more comprehensive understanding of all facets of the smoking cessation process."
 Among the special support services offered ProStep users are a toll- free hotline manned by smoking cessation specialists and a pharmacist counseling program. In clinical trials using a single dosage strength of 22mg/day for six to eight weeks, quit rates with ProStep were significantly higher than those seen with placebo, when both were used with counseling.
 Elan is a leader in the specialized health care field of advanced reformulation and drug delivery, concentrating on improved drug absorption and utilization. It operates research and manufacturing facilities in Athlone, Ireland; Gainesville, Ga.; Enschede, Netherlands; Manila, Philippines; Brea, Calif.; and Cambridge, Mass.
 -0- 06/15/92
 CONTACT: Brian Crotty of Elan, 800-252-3526; or Thomas Redington, 203-222-7399 or 212-926-1733, for Elan
 (ELN) CO: ELAN CORPORATION PLC IN: HOU -- NY021 -- X431 06/15/92
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 15, 1992
Words:474
Previous Article:XHIBITION FEATURES A WEALTH OF INFORMATION ON OPEN SYSTEMS, DISTRIBUTED COMPUTING
Next Article:RKK SIGNS TEAMING AGREEMENT WITH CHEMICAL WASTE MANAGEMENT
Topics:


Related Articles
ELAN TO DOUBLE SIZE OF GAINESVILLE, GA. FACILITY FOR PRODUCTION OF NICOTINE PATCH AND OTHER DRUGS
ELAN'S SMOKING CESSATION PRODUCT -- FIRST OTC LAUNCH
U.S. FDA APPROVES ELAN'S NICOTINE PATCH
/FIRST ADD -- NY081 -- ELAN'S NICOTINE PATCH APPROVED BY FDA/
ELAN STEPS UP PROSTEP PATCH PRODUCTION FOR CYANAMID'S LEDERLE; MORE THAN FOUR MILLION SHIPPED THUS FAR
COURT RULES IN FAVOR OF CYGNUS MOTION FOR SUMMARY JUDGMENT; DISMISSES IMPORTANT PARTS OF PATENT INFRINGEMENT SUIT
CYGNUS SHIPS ITS NICOTINE PATCH
LEDERLE ANNOUNCES PROSTEP NOW FULLY AVAILABLE; NATIONAL ADVERTISING BEGINS ON THE OLYMPICS THIS WEEK
ELAN REPORTS FIRST QUARTER FISCAL 1993 RESULTS
USE OF ELAN'S PATCH DOUBLES QUIT RATE AT ONE YEAR

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters